

Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1238, 2000-01, pp. : 20-20
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


Serious adverse CV events with varenicline
Reactions Weekly, Vol. 1, Iss. 1360, 2011-01 ,pp. :


Off-label Vistide use associated with serious adverse events
Reactions Weekly, Vol. 1, Iss. 1338, 2011-01 ,pp. :


Effect of Information on Reported Adverse Events in a Placebo-Controlled Trial
By Michael Ossege Thomas Sycha
Drug Safety, Vol. 28, Iss. 1, 2005-01 ,pp. :

